FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial

This publication has 23 references indexed in Scilit:

• Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin
  JACC: Heart Failure, 2025
• IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial
  Nature Medicine, 2024
• Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
  Diabetologia, 2021
• Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
  JACC, 2020
• Klotho, Fibroblast Growth Factor-23, and the Renin–Angiotensin System — an Analysis from the PEACE Trial
  European Journal of Heart Failure, 2019
• Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome
  JAMA Cardiology, 2018
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
  New England Journal of Medicine, 2017
• Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
  JACC, 2017
• Circulating fibroblast growth factor‐23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease
  Diabetes/Metabolism Research and Reviews, 2016
• C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
  JACC, 2007